CRISPR-Engineered Immunotherapy for Metastatic GI Tract Cancers
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Researchers are testing the use of tumor-infiltrating lymphocytes, a type of immunotherapy, against advanced pancreatic cancer.
Modern immunology shows that Coley’s principles of immune stimulation were indeed on target, and today the field of cancer immunology has become a highly sophisticated specialty. Indeed, cancer vaccines have caught the imagination of the public and of researchers who are investigating and developing these vaccine therapies. But the clinical translation of cancer vaccines into…
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
A clinical trial compares the effectiveness of two different types of immunotherapy with standard treatment after pancreatic cancer surgery.
Exploring the effectiveness of the immunotherapy combination of cancer vaccines and a checkpoint blockade drug against metastatic pancreatic cancer.